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Aims
This study aimed to compare the change in health-related quality of life of patients receiving 
a traditional cemented monoblock Thompson hemiarthroplasty compared with a modern 
cemented modular polished-taper stemmed hemiarthroplasty for displaced intracapsular 
hip fractures.
Patients and Methods
This was a pragmatic, multicentre, multisurgeon, two-arm, parallel group, randomized 
standard-of-care controlled trial. It was embedded within the WHiTE Comprehensive Cohort 
Study. The sample size was 964 patients. The setting was five National Health Service 
Trauma Hospitals in England. A total of 964 patients over 60 years of age who required 
hemiarthroplasty of the hip between February 2015 and March 2016 were included. A 
standardized measure of health outcome, the EuroQol (EQ-5D-5L) questionnaire, was 
carried out on admission and at four months following the operation.
Results
Of the 964 patients enrolled, 482 died or were lost to follow-up (50%). No significant 
differences were noted in EQ-5D between groups, with a mean difference at four months of 
0.037 in favour of the Exeter/Unitrax implant (95% confidence interval (CI) 0.014 to 0.087, 
p = 0.156), rising to 0.045 (95% CI 0.007 to 0.098, p = 0.09) when patients who died were 
excluded. The minimum clinically important difference for EQ-5D-5L used in this study is 
0.08, therefore any benefit between implants is unlikely to be noticeable to the patient. 
There was no difference in mortality or mobility score.
Conclusion
Allowing for the high rate of loss to follow-up, the use of the traditional Thompson 
hemiarthroplasty in the treatment of the displaced intracapsular hip fracture shows no 
difference in health outcome when compared with a modern cemented hemiarthroplasty.
Cite this article: Bone Joint J 2018;100-B:352–60.
Worldwide, 1.3 million patients sustain a frac-
ture of the hip each year, leading to1.75 million
disability-adjusted life years lost, and account-
ing for 1.4% of the total healthcare burden in
established market economies.1 In the United
Kingdom, there are 70 000 such fractures each
year which is forecast to increase to 100 000
by 2020.1,2 Around half of these are intracap-
sular fractures which are usually treated using
a hemiarthroplasty;3,4 around 19 000 hemiar-
throplasties are performed each year in Eng-
land, Wales and Northern Ireland.5
The Thompson prosthesis is a generic mon-
oblock hemiarthroplasty designed 65 years
ago and is intended for cemented implantation
(Fig. 1).6 As it is a monoblock, there is limited
scope for adjustment of length and offset. At
five years, the cemented Thompson stem has a
published survival of 95%; the list price, as
published and available from trust finance
departments, is £327, including United King-
dom Value Added Tax (VAT).
The Exeter hip arthroplasty system (Stryker
Ltd., Newbury, United Kingdom) is widely
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used as a total hip arthroplasty (THA) system in arthritis of
the hip.7 Used with the large Unitrax femoral head
(Stryker), the Exeter stem may now be used as a hemiar-
throplasty; as a modular system, this has the advantage of
allowing changes in length and offset following cementa-
tion (Fig. 2). While the Exeter stem has excellent long-term
survival in THA, no data exists regarding its use as a hem-
iarthroplasty with the Unitrax head. The list price of this
implant combination, as published and available from trust
finance departments, is around £1442, including VAT.
The Orthopaedic Device Evaluation Panel (ODEP) pro-
duces ratings for THA prostheses used in the United King-
dom, based on length of follow-up and quality of evidence.8
In the United Kingdom, the National Institute of Health
and Care Excellence (NICE) has recommended the use of
‘proven’ cemented stem designs with an ODEP rating of at
least 3B (97% survival at three years) when used as a THA,
explicitly advising against the use of the Thompson pros-
thesis.9 In the absence of randomised trials, this guidance
was based on data from studies of THA and from expert
opinion. In fact, no hemiarthroplasty has an ODEP rating,
including the Thompson and the Exeter/Unitrax hemiar-
throplasty.
The aim of this trial is to compare the change in health-
related quality of life of patients receiving a cemented mon-
oblock Thompson versus a cemented modular polished
taper stem (Exeter/Unitrax) for displaced intracapsular
fractures requiring hemiarthroplasty.
Patients and Methods
Study design and participants. This was a multicentre,
multisurgeon, two-arm, parallel group, randomized stand-
ard-of-care controlled trial.10 It was embedded within the
World (formerly Warwick) Hip Trauma Evaluation
(WHiTE) Comprehensive Cohort Study.11 The trial was
approved by the Research Ethics Committee and reported
in accordance with the trial protocol and Consolidated
Standards of Reporting Trials statement.
The WHiTE Study is a large cohort study examining a
range of outcomes including health-related quality of life
using EuroQol (EQ-5D-5L) in patients following fracture
of the hip, and allows embedding of randomized controlled
trials within this patient cohort.12-15 The WHiTE 3: HEMI
trial is an embedded trial that compared the Thompson
hemiarthroplasty with the Exeter/Unitrax.16
Hypothesis. The null hypothesis was that there is no differ-
ence in health-related quality of life at four months post
injury between patients over 60 years of age with an AO/
OTA type B3 fracture (displaced, intracapsular) of the hip
treated with an Exeter/Unitrax compared with those
treated with Thompson.17
Aims. The primary objective was to compare observed dif-
ferences in patients’ health-related quality of life between
the trial treatment groups at four months post-injury. The
secondary objectives were to compare mortality, mobility
score, reoperation and cause, length of acute ward stay and
revision at four months. We also measured radiological leg
length discrepancy as per Bidwai and Willett.18
Outcome assessment. We augmented the existing National
Hip Fracture Database dataset with the United Kingdom
Core Outcome Set for Hip Fracture Research.19 This
includes the EQ-5D-5L at baseline (retrospective, prior to
fracture) and four months post-fracture.12 Four months
represents a routine follow-up point for the National Hip
Fracture Database, and is considered to be the point at
which recovery following hip fracture plateaus (Fig. 3).9,20
The EQ-5D-5L provides a score of 0 in the event of mortal-
ity, ensuring patients that die during the follow-up period
can be included in the final assessment. EQ-5D correlates
strongly with a hip-specific patient-reported outcome
measurement, the Oxford Hip Score, and is as responsive to
changes over time in patients having hemiarthroplasty.20
Radiographs and notes (operation note and discharge
summary) were studied in order to capture perioperative
complications, length of hospital stay, and discharge
address. Radiological neck lengths were calculated using
Fig. 1
Plain radiograph of a cemented Thompson monoblock
hemiarthroplasty.
Fig. 2
Plain radiograph of a cemented Exeter polished
taper stem with a Unitrax head (modular implant).
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standard hospital-based radiology software and scored by
two independent orthopaedic surgeons (see Supplementary
material for a full list of the CORNET Collaborators).
These measurements were repeated and a mean value iden-
tified for each patient. Standardization was achieved using
a known value to provide a sizing ratio for radiological
measurements (the implant head size).
Inclusion and exclusion criteria. All patients over the age of
60 years, receiving a hemiarthroplasty for a type B3 frac-
ture of the hip were eligible for inclusion. Patients with pre-
existing symptomatic hip arthritis were excluded from the
trial.
Consent. Consent was conducted under the same condi-
tions as other studies in the WHiTE cohort.11,21 Where
patients lacked capacity, we approached an appropriate
consultee. Where a personal consultee was available, they
were provided with the study information and their agree-
ment to patient enrolment was recorded. where a personal
consultee was not available, a nominated consultee was
identified to advise the research team. At the first appropri-
ate time when the patient had regained capacity, informed
consent for continuation was obtained from the patient.
For those patients with permanent cognitive impairment, a
Personal Consultee was asked to give agreement for contin-
uation in the study.
Power and sample size. The sample size was calculated as
964 patients based on standard deviation for EQ-5D at
four months’ post-surgery of approximately 0.3 points20
and a minimum clinically important difference for an EQ-
5D of 0.08.22 This assumes an approximately normal dis-
tribution (no other distributional assumption has been
found to be preferable to normality, based on the authors’
experience from previous studies of this outcome measure
in this population),20,23 a 1:1 allocation ratio, a 30% loss to
follow-up, a type 1 error rate of 5%, and power of 90%.
Treatment allocation. Allocation sequences were created
using a computer-generated random number sequence via
an online randomization portal. After registration on the
portal, patients were allocated their treatment before sur-
gery and that allocation recorded centrally on the online
system. Participants were enrolled by members of the Col-
laborative Orthopaedic Research Network (CORNET)
trainee collaborative or trial research associates. 
Blinding. Participants were blinded to the treatment alloca-
tion. The operating surgeon could not be blinded to the
allocation but took no part in the assessment of the primary
outcome measurement. The EQ-5D is a patient-reported
measure and was collected independently from the surgical
team.
Trial treatments. Participants were randomized to receive
either a cemented Thompson hemiarthroplasty or a
cemented Exeter/Unitrax. Patients received general or
regional anaesthesia at the discretion of the anaesthetist.
Surgery was performed under the care of any of the consult-
ant surgeons in the collaborating centres. The large number
of surgeons and the wide skill mix was intended to elimi-
nate the ‘surgeon effect’ such that stratification by surgeon
was not required.24 Pre and postoperative management was
as per the standard of care in the unit, according to NICE
guidance.9
Methods and assessments. Participants were followed up
centrally. Techniques used to ensure minimum loss to
follow-up included collecting multiple contact addresses,
telephone numbers, mobile phone numbers and email
addresses during enrolment.
Statistical analysis. The primary outcome measure was
health related quality of life according to the EuroQol five
domain questionnaire (EQ-5D). Groups were compared on
an intention-to-treat basis at four months from the index
fracture. In order to avoid overestimating the effects of the
intervention or treatment pathway, we used death-adjusted
estimates.25 The differences between treatment groups were
assessed using an independent samples t-test with p-values
less than 0.05 considered significant.
As a sensitivity analysis, regression analyses were per-
formed to adjust for any imbalance between treatment
groups in patient baseline (pre-injury) EQ-5D, age and gen-
der. The fixed effects linear regression model was general-
ized by adding a random effect for recruiting centre to
allow for possible heterogeneity in patient outcomes due
more generally to the recruiting centre. The mixed-effects
regression was the definitive analysis and was undertaken
using the specialist mixed-effects modelling functions avail-
able in the software package R (R Foundation, Vienna,
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Austria). EQ-5D data were assumed to be approximately
normally distributed.20,23
Secondary analyses (mortality, walking ability, length of
stay, complications and radiological neck length) were
undertaken using the above strategy for approximately
normally distributed outcome measures. For dichotomous
outcome variables, mixed effects logistic regression analysis
was undertaken with results presented as odds ratios (OR)
(and 95% confidence intervals (CI)) between the trial
groups.
Results
Baseline outcomes. The target of 964 patients was
recruited between Feb 2015 and March 2016 (Fig. 4),
and was faster than estimated thanks to the efforts of the
CORNET trainee research collaborative. Of 964
patients recruited, 704 (73%) were women, and the
mean age was 83.7 (7.3) for the Thompsons group and
83.9 (7.9) for the Exeter/ Unitrax group. The mean
length of surgery was 80 minutes (42 to 205) for the
Exeter/Unitrax and 70 minutes (27 to 197) for the
Thompson. A total of 47 patients crossed over to the
other treatment group, 15 of whom crossed over to an
Exeter/Unitrax and 32 to a Thompson; this generally
happened when the alternative implant system was una-
vailable at the time of surgery (Table I).
Primary outcome
Of the 964 patients recruited, 482 had a valid EQ-5D at
four months (50%) (Table I). Of these, 283 self-responded
(60%) and 186 were reported by a proxy (40%) (Fig. 5). At
four months, including patients who had died, the adjusted
mean EQ-5D-5L was 0.321 (SD 0.348, n = 303) in the
Thompsons group and 0.379 (SD 0.358, n = 315) in
the Exeter group, giving a mean difference of 0.037 (95%
CI -0.014 to 0.087, p = 0.156) in favour of the Exeter/Uni-
trax. Excluding patients who had died, this difference was
0.045 (95% CI -0.007 to 0.098, p = 0.09) (Table II).
Dimensions of health at four months are shown in Table III.
Secondary outcomes. Mortality was 15% overall with no
difference between the two implants: 73 in the Thompson
group and 74 in the Exeter/Unitrax group. The adjusted
OR for mortality was 1.02 (95% CI 0.72 to 1.46,
p = 0.911).
Walking ability was similar in the two groups: using
ordinal logistic regression, the OR for severe walking diffi-
culty was 0.76 (95% CI 0.54 to 1.06, p = 0.107 favouring
the Exeter/Unitrax (Table IV).
Mean length of stay was slightly higher in the Thompson
group (9.67 days for Thompson, 9 days for Exeter/Unitrax;
p = 0.039, Fig. 6). There was no difference in complications
between the two groups (Table V). There were three cases
of implant revision in each group.
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There was no difference in the multivariate mixed-effects
regression analysis in radiologically-measured mean neck
length between the two prostheses (Thompson, 3.01 mm,
standard deviation (SD) 7.26; Exeter/Unitrax, 2.91 mm,
SD 7.61, p= 0.834, Fig. 7).
Discussion
This trial found no evidence of a difference in health-related
quality of life for patients with displaced intracapsular hip
fracture treated with a traditional Thompson hemiarthro-
plasty compared with a modern cemented modular hemiar-
Table I. Patient characteristics
Characteristic Thompson (n = 482) Exeter/Unitrax (n = 482)
Female, n (%) 326 (67.6) 326 (67.6)
Male, n (%) 156 (32.4) 156 (32.4)
Mean age, yrs (SD) 83.7 (7.3) 83.9 (7.9)
Admitted from, n (%)
Own home/sheltered housing 271 (73.2) 277 (72.9)
Residential care 57 (15.4) 57 (15)
Nursing home 33 (8.9) 29 (7.6)
Rehabilitation unit 2 (0.5) 2 (0.5)
This hospital 4 (1.1) 6 (1.6)
Other hospital within same trust 1 (0.3) 9 (2.4)
Other hospital trust 2 (0.5) 0 (0)
ASA,26 n (%)
1 1 (0.3) 2 (0.5)
2 78 (21.2) 84 (22.2)
3 240 (65.2) 230 (60.7)
4 49 (13.3) 63 (16.6)
Mean time from admission to surgery, hrs (SD) 28.2 (23.4) 28.5 (21.0)
Mean preoperation AMTS19(SD) 6.4 (3.8) 6.6 (3.7)
Mean postoperation AMTS19(SD) 6.1 (3.8) 6.3 (3.9)
ASA, American Society of Anesthesiologists; AMTS, Abbreviated Mental Test Score (scored from 1 and 10); SD, standard 
deviation
Randomized
(n = 964)
Allocated to Thompson (n = 482)
•  Received Thompson (n = 458)
•  Received Exeter (n = 15)
    •  Clinical reason (n = 12)
    •  Logistical reason (n = 3)
•  Alternative procedure (n = 9)
Allocated to Exeter (n = 482)
•  Received Exeter (n = 439)
•  Received Thompson (n = 32)
     •  Clinical reason (n = 22)
     •  Logistical reason (n = 10)
•  Alternative procedure (n = 11)
Full consent (n = 311)
•  Withdrawn or died (n = 101)
•  Routine data only (n = 70)
Deaths (n = 74)
•  Before consent (n = 31)
•  After consent (n = 43)
Follow-up:
Primary outcome: EQ-5D-5L
•  At 4 mths (n = 315/336, 94%)
Withdrawn (n = 76)
Before consent (n = 70); after consent (n = 6)
•  Didn’t want to do research (n = 18)
•  Didn’t want to do questions (n = 8)
•  No reason (n = 10)
•  Other reason (n = 40)
     •  Failed contact (n = 8)
     •  No consultee available (n = 3)
     •  No operation (n = 4)
     •  No reason (n = 6)
     •  No to research (n = 12)
     •  Randomized in error (n = 2)
     •  Terminally ill (n = 2)
     •  Too frail or old (n = 3)
Withdrawn (n = 95)
Before consent (n = 85); after consent (n = 10)
•  Didn’t want to do research (n = 25)
•  Didn’t want to do questions (n = 10)
•  No reason (n = 11)
•  Other reason (n = 49)
     •  Failed contact (n = 15)
     •  No consultee available (n = 2)
     •  No operation (n = 2)
     •  No reason (n = 7)
     •  No to research (n = 16)
     •  Randomized in error (n = 3)
     •  Terminally ill (n = 1)
     •  Too frail or old (n = 3)
WHiTE3: HEMI. Warwick Hip Trauma
Evaluation Study 3: Hemiarthroplasty
Full consent (n = 306)
•  Withdrawn or died (n = 112)
•  Routine data only (n = 64)
Deaths (n = 73)
•  Before consent (n = 27)
•  After consent (n = 46)
Follow-up:
Primary outcome: EQ-5D-5L
• At 4 mths (n = 303/323, 90%)
Consolidated Standards of Reporting Trials (CONSORT) flowchart.
Fig. 5
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throplasty. The difference between the two was not
statistically significant and did not reach the accepted min-
imum clinically important difference of 0.08. In terms of
secondary outcomes, walking status, mortality and radio-
logical neck length measurements were similar in the two
groups. There was a small difference in length of stay
favouring the Exeter/Unitrax implant.
This large multicentre randomized controlled trial bene-
fitted from a pragmatic design using the United Kingdom
Core Outcome Set for hip fracture research including a
patient-reported primary outcome measure (EuroQol
(EQ)-5D) that is known to be suitable for proxy use. The
benefits of this are that the trial could include the cohort of
hip fracture patients with cognitive impairment and is gen-
eralizable to this population. Patients were blinded to their
treatment allocation.
Recruitment was more rapid than predicted due in part
to the involvement of the CORNET trainee collaborative.
This group of orthopaedic trainees could ensure that suita-
ble patients were appropriately randomized outside normal
office hours, increasing the efficiency of the trial. Use of
trainee collaboratives has numerous benefits to clinical
Table II. Adjusted EuroQol EQ-5D-5L at four months
Thompson Exeter/Unitrax Adjusted difference (95% CI) p-value*
Mean EQ-5D (SD, n) 0.321 (0.348, 303) 0.379 (0.358, 315) 0.037 (-0.014 to 0.087) 0.156
Mean EQ-5D† (SD, n) 0.420 (0.341, 231) 0.496 (0.332, 241) 0.045 (-0.007 to 0.098) 0.090
*p-value from mixed effects regression analysis, with treatment group, age group, gender and baseline EQ-5D score as covariates 
(fixed effects) and recruiting centre as a random effect
†EQ-5D calculated exclusive of patients who died (for whom EQ-5D is 0)
Table III. Counts and percentages of four-month EuroQol EQ-5D by domain and level, by intervention group
Domain Thompson Exeter/Unitrax
Level 1 2 3 4 5 Total 1 2 3 4 5 Total
Mobility, n (%) 27 (11) 53 (22) 77 (32) 49 (20) 38 (16) 244 40 (16) 63 (25) 73 (29) 43 (17) 32 (13) 251
Self-care, n (%) 85 (35) 40 (16) 35 (14) 18 (7) 66 (27) 244 112 (16) 42 (25) 34 (29) 10 (17) 53 (13) 251
Usual activities, n (%) 44 (18) 41 (17) 44 (18) 28 (12) 85 (35) 242 57 (23) 48 (19) 50 (20) 20 (8) 75 (30) 250
Pain, n (%) 88 (37) 62 (26) 52 (22) 29 (12) 6 (3) 237 108 (44) 64 (26) 54 (22) 16 (6) 5 (2) 247
Anxiety, n (%) 115 (49) 53 (22) 47 (20) 13 (6) 8 (3) 236 126 (51) 52 (21) 47 (19) 18 (19) 5 (7) 248
Table IV. Mobility at four months post-fracture
Thompson (n = 242) Exeter/Unitrax (n = 252)
Freely mobile without aids, n (%) 15 (6) 16 (6)
Mobile outdoors with one aid, n (%) 38 (16) 47 (19)
Mobile outdoors with two aids or frame, n (%) 19 (8) 34 (13)
Some indoor mobility but never goes outside without help, n (%) 135 (56) 123 (49)
No functional mobility (using lower limbs), n (%) 35 (14) 32 (13)
Table V. Complications at four months; estimated raw and adjusted odds ratios based on intention-to-treat analysis
Thompson (n = 482) Exeter/Unitrax (n = 482) OR Adjusted§ 95% CI p-value
Local complications* 19 28 1.502 1.507 0.828 to 2.741 0.179
Systemic complications† 6 9 1.509 1.513 0.530 to 4.316 0.439
Unrelated adverse events‡ 75 72 0.953 0.950 0.665 to 1.358 0.779
OR, odds ratio; CI, confidence interval
*Erythema, serious drainage, purulent drainage, microbiological infection, dehiscence, antibiotics, debridement, implant revision, neurological 
injury, tendon injury, deep vein thrombosis, wound infection, failure of fixation, dislocation
†Blood transfusion
‡Pneumonia, urinary tract infection, cerebrovascular accident, myocardial infarction, other
§Mixed effects regression based on a complete case analysis with treatment group, age group and gender as covariates (fixed effects) and 
recruiting centre as a random effect
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research and should be considered carefully during initial
trial design.26
A limitation of this trial was the large number of with-
drawals. As 50% of those enrolled in the trial withdrew, the
trial did not quite reach the 90% planned statistical power,
which would have required data from 337 patients in each
group, but easily passed the sample size required for 80%
power (252 in each group). The number of patients who
withdrew was higher than anticipated but not wholly unex-
pected in a trial involving a particularly frail older popula-
tion. The results of this trial should not be extrapolated to
the patients who were excluded because they were having a
total hip arthroplasty. THA is generally offered to patients
who have higher pre-injury walking status. Recent research
suggests that more patients would benefit from total hip
replacement than currently receive it.27
The follow-up period for this trial was four months. The
long-term survival of these implants is not examined. Previ-
ously, survival analysis performed on the Thompson stem
has demonstrated stem survival of over 95% at five years,
and a mortality of 70% at six years, with no revision sur-
gery beyond this point.28 No comparable data exist on the
Exeter/Unitrax prosthesis. More recent evidence from a 12-
year follow-up of patients treated with either total hip
arthroplasty or hemiarthroplasty has demonstrated a mor-
tality rate of 20% overall with no difference between func-
tional outcomes, mortality or complications.29
This trial provides some evidence that the Thompson
hemiarthroplasty can offer a comparable outcome with a
modern modular stem in this patient group. The Thompson
is considerably lower in cost than the more modern hemi-
arthroplasty implants recommended by NICE.
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Take home message:
- A cemented Thompson hemiarthroplasty may provide simi-
lar health-related quality of life compared with modern
implants for patients with a displaced intracapsular fracture of the hip.
Supplementary material
Tables providing further information, along with a
full list of the CORNET Collaborators, are available
alongside this article at www.bjj.boneandjoint.org.u
Twitter
Follow A. L. Sims @alsims16
Follow M. R. Reed* @mikereednhs
Follow CORNET Trainee Collaborative @CornetResearch
References
1. Johnell O, Kanis J. An estimate of the worldwide prevalence, mortality and disabil-
ity associated with hip fracture. Osteoporos Int 2004;15:897–902.
2. Burge RT, Worley D, Johansen A, Bhattacharyya S, Bose U. The cost of osteo-
porotic fractures in the UK: projections for 2000–2020. J Med Econ 2001;4:51–62.
3. RCP National Hip Fracture Database annual report 2015. https://www.nhfd.co.uk/
2015report. London: RCP, 2016.
4. No authors listed. National Institute for Health and Care Excellence (NICE)
www.nice.org.uk (date last accessed 7 November 2017).
5. RCoP National Hip Fracture Database annual report 2016. https://www.nhfd.co.uk/
2016report. London: RCP, 2016.
6. Thompson FR. Vitallium intramedullary hip prosthesis, preliminary report. N Y State
J Med 1952;52:3011–3020.
7. No authors listed. National Joint Registry (NJR) 13th Annual Report, 2016. http://
www.njrcentre.org.uk/njrcentre/Portals/0/Documents/England/Reports/
13th%20Annual%20Report/07950%20NJR%20Annual%20Re-
port%202016%20ONLINE%20REPORT.pdf (date last accessed 7 November 2017).
8. No authors listed. Orthopaedic Data Evaluation Panel (ODEP) http://
www.odep.org.uk/ (date last accessed 7 November 2017).
9. No authors listed. The management of hip fracture in adults. 2011.
www.nice.org.uk/guidance/cg124 (date last accessed 11 December 2017).
10. Costa ML, Griffin XL, Parsons N, Dritsaki M, Perry D, on behalf of the Bone &
Joint Journal Research Methods Group. Efficacy versus effectiveness in clinical
trials. Bone Joint J 2017;99-B:419–420.
11. Costa ML, Griffin XL, Achten J, et al. World Hip Trauma Evaluation (WHiTE):
framework for embedded comprehensive cohort studies. BMJ Open 2016;6:011679.
12. No authors listed. EQ-5D. www.EuroQol.org (date last accessed 7 November 2017).
13. Griffin XL, Achten J, Parsons N, et al. The Warwick Hip Trauma Evaluation–an
abridged protocol for the WHiTE Study. Bone Joint Res 2012;1:310–314.
14. Griffin XL, Parsons N, McArthur J, Achten J, Costa ML. The Warwick Hip
Trauma Evaluation One: a randomised pilot trial comparing the X-Bolt Dynamic Hip
Plating System with sliding hip screw fixation in complex extracapsular hip fractures:
WHiTE (One). Bone Joint J 2016;98-B:686–689.
15. Griffin XL, Parsons N, Achten J, Costa ML. A randomised feasibility study com-
paring total hip arthroplasty with and without dual mobility acetabular component in
the treatment of displaced intracapsular fractures of the proximal femur: The War-
wick Hip Trauma Evaluation Two : WHiTE Two. Bone Joint J 2016;98-B:1431–1435.
–30
0
20
40
60
80
100
–20 –10 0 10 20 30
Fr
eq
ue
nc
y
Neck length (mm)
–30
0
20
40
60
80
100
–20 –10 0 10 20 30
Fr
eq
ue
nc
y
Neck length (mm)
Graph showing the distribution of difference in neck length (mm), for a) Thompson and b) Exeter/Unitrax implants,
divided into 5 mm categories: -35 mm to -30 mm; -30 mm to -25 mm; -25 mm to -20 mm; and so on. The vertical dashed
lines indicate the mean values.
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